Three Drug Combinations for Sleeping Sickness
Author Information
Author(s): Priotto Gerardo, Fogg Carole, Balasegaram Manica, Erphas Olema, Louga Albino, Checchi Francesco, Ghabri Salah, Piola Patrice
Primary Institution: Epicentre, Paris, France
Hypothesis
The study aimed to compare the efficacy and safety of three drug combinations for treating late-stage human African trypanosomiasis.
Conclusion
The N+E combination appears to be a promising first-line therapy for sleeping sickness, although further studies are needed.
Supporting Evidence
- The N+E combination had a cure rate of 94.1%, significantly higher than the other combinations.
- Adverse events were less frequent and severe with the N+E combination.
- The trial was stopped early due to unacceptable toxicity in one treatment arm.
Takeaway
Doctors tested three different medicine combinations to help people with a serious illness called sleeping sickness, and one combination worked much better than the others.
Methodology
This was a randomized, open-label, active control, parallel clinical trial comparing three drug combinations.
Potential Biases
The non-blinded nature of the trial may have influenced the observation of adverse events.
Limitations
The trial was terminated early due to high fatality rates in one treatment arm, limiting the ability to draw definitive conclusions.
Participant Demographics
54 participants (27 men and 27 women, age range 5–62 years) diagnosed with stage 2 sleeping sickness.
Statistical Information
P-Value
0.003
Statistical Significance
p = 0.003
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website